메뉴 건너뛰기




Volumn 21, Issue 4, 2013, Pages 895-903

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients

Author keywords

[No Author keywords available]

Indexed keywords

AFM 13; ANTINEOPLASTIC AGENT; CD16 ANTIGEN; CD30 ANTIGEN; INTERLEUKIN 2; MACROPHAGE MIGRATION INHIBITION FACTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

EID: 84878582221     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.14     Document Type: Article
Times cited : (94)

References (50)
  • 1
    • 53549114206 scopus 로고    scopus 로고
    • NK cells and cancer immunosurveillance
    • Waldhauer, I and Steinle, A (2008). NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943.
    • (2008) Oncogene , vol.27 , pp. 5932-5943
    • Waldhauer, I.1    Steinle, A.2
  • 2
    • 53549124398 scopus 로고    scopus 로고
    • NKG2D ligands in tumor immunity
    • Nausch, N and Cerwenka, A (2008). NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
    • (2008) Oncogene , vol.27 , pp. 5944-5958
    • Nausch, N.1    Cerwenka, A.2
  • 3
    • 33745567831 scopus 로고    scopus 로고
    • Self-tolerance of natural killer cells
    • Raulet, DH and Vance, RE (2006). Self-tolerance of natural killer cells. Nat Rev Immunol 6: 520-531.
    • (2006) Nat Rev Immunol , vol.6 , pp. 520-531
    • Raulet, D.H.1    Vance, R.E.2
  • 4
    • 37549028403 scopus 로고    scopus 로고
    • Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: A lesson for the use of recombinant immunoreceptors as an immunological tool
    • Hershkovitz, O, Jarahian, M, Zilka, A, Bar-Ilan, A, Landau, G, Jivov, S et al. (2008). Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology 18: 28-41.
    • (2008) Glycobiology , vol.18 , pp. 28-41
    • Hershkovitz, O.1    Jarahian, M.2    Zilka, A.3    Bar-Ilan, A.4    Landau, G.5    Jivov, S.6
  • 5
    • 82755186747 scopus 로고    scopus 로고
    • Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44
    • Rosental, B, Brusilovsky, M, Hadad, U, Oz, D, Appel, MY, Afergan, F et al. (2011). Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol 187: 5693-5702.
    • (2011) J Immunol , vol.187 , pp. 5693-5702
    • Rosental, B.1    Brusilovsky, M.2    Hadad, U.3    Oz, D.4    Appel, M.Y.5    Afergan, F.6
  • 6
    • 34250803843 scopus 로고    scopus 로고
    • Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44
    • Hershkovitz, O, Jivov, S, Bloushtain, N, Zilka, A, Landau, G, Bar-Ilan, A et al. (2007). Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry 46: 7426-7436.
    • (2007) Biochemistry , vol.46 , pp. 7426-7436
    • Hershkovitz, O.1    Jivov, S.2    Bloushtain, N.3    Zilka, A.4    Landau, G.5    Bar-Ilan, A.6
  • 7
    • 37049037976 scopus 로고    scopus 로고
    • Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells
    • Pogge von Strandmann, E, Simhadri, VR, von Tresckow, B, Sasse, S, Reiners, KS, Hansen, HP et al. (2007). Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27: 965-974.
    • (2007) Immunity , vol.27 , pp. 965-974
    • Pogge Von Strandmann, E.1    Simhadri, V.R.2    Von Tresckow, B.3    Sasse, S.4    Reiners, K.S.5    Hansen, H.P.6
  • 8
    • 67650507057 scopus 로고    scopus 로고
    • The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
    • Brandt, CS, Baratin, M, Yi, EC, Kennedy, J, Gao, Z, Fox, B et al. (2009). The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 206: 1495-1503.
    • (2009) J Exp Med , vol.206 , pp. 1495-1503
    • Brandt, C.S.1    Baratin, M.2    Yi, E.C.3    Kennedy, J.4    Gao, Z.5    Fox, B.6
  • 9
    • 24944500112 scopus 로고    scopus 로고
    • Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance
    • Oppenheim, DE, Roberts, SJ, Clarke, SL, Filler, R, Lewis, JM, Tigelaar, RE et al. (2005). Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6: 928-937.
    • (2005) Nat Immunol , vol.6 , pp. 928-937
    • Oppenheim, D.E.1    Roberts, S.J.2    Clarke, S.L.3    Filler, R.4    Lewis, J.M.5    Tigelaar, R.E.6
  • 10
    • 23944519927 scopus 로고    scopus 로고
    • Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells
    • Coudert, JD, Zimmer, J, Tomasello, E, Cebecauer, M, Colonna, M, Vivier, E et al. (2005). Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106: 1711-1717.
    • (2005) Blood , vol.106 , pp. 1711-1717
    • Coudert, J.D.1    Zimmer, J.2    Tomasello, E.3    Cebecauer, M.4    Colonna, M.5    Vivier, E.6
  • 11
    • 0037126310 scopus 로고    scopus 로고
    • Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
    • Groh, V, Wu, J, Yee, C and Spies, T (2002). Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
    • (2002) Nature , vol.419 , pp. 734-738
    • Groh, V.1    Wu, J.2    Yee, C.3    Spies, T.4
  • 12
    • 34249295619 scopus 로고    scopus 로고
    • Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
    • Kaiser, BK, Yim, D, Chow, IT, Gonzalez, S, Dai, Z, Mann, HH et al. (2007). Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486.
    • (2007) Nature , vol.447 , pp. 482-486
    • Kaiser, B.K.1    Yim, D.2    Chow, I.T.3    Gonzalez, S.4    Dai, Z.5    Mann, H.H.6
  • 13
    • 0041737499 scopus 로고    scopus 로고
    • Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
    • Salih, HR, Antropius, H, Gieseke, F, Lutz, SZ, Kanz, L, Rammensee, HG et al. (2003). Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389-1396.
    • (2003) Blood , vol.102 , pp. 1389-1396
    • Salih, H.R.1    Antropius, H.2    Gieseke, F.3    Lutz, S.Z.4    Kanz, L.5    Rammensee, H.G.6
  • 14
    • 42649119742 scopus 로고    scopus 로고
    • Soluble NKG2D ligands: Prevalence, release, and functional impact
    • Salih, HR, Holdenrieder, S and Steinle, A (2008). Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 13: 3448-3456.
    • (2008) Front Biosci , vol.13 , pp. 3448-3456
    • Salih, H.R.1    Holdenrieder, S.2    Steinle, A.3
  • 15
    • 69349104067 scopus 로고    scopus 로고
    • Differential clinical signifcance of individual NKG2D ligands in melanoma: Soluble ULBP2 as an indicator of poor prognosis superior to S100B
    • Paschen, A, Sucker, A, Hill, B, Moll, I, Zapatka, M, Nguyen, XD et al. (2009). Differential clinical signifcance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15: 5208-5215.
    • (2009) Clin Cancer Res , vol.15 , pp. 5208-5215
    • Paschen, A.1    Sucker, A.2    Hill, B.3    Moll, I.4    Zapatka, M.5    Nguyen, X.D.6
  • 16
    • 61349167118 scopus 로고    scopus 로고
    • Clinical signifcance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: High expression of ULBP2 is an indicator of poor prognosis
    • Li, K, Mandai, M, Hamanishi, J, Matsumura, N, Suzuki, A, Yagi, H et al. (2009). Clinical signifcance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58: 641-652.
    • (2009) Cancer Immunol Immunother , vol.58 , pp. 641-652
    • Li, K.1    Mandai, M.2    Hamanishi, J.3    Matsumura, N.4    Suzuki, A.5    Yagi, H.6
  • 17
    • 84864131272 scopus 로고    scopus 로고
    • Comprehensive analysis of NKG2D ligand expression and release in leukemia: Implications for NKG2D-mediated NK cell responses
    • Hilpert, J, Grosse-Hovest, L, Grünebach, F, Buechele, C, Nuebling, T, Raum, T et al. (2012). Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 189: 1360-1371.
    • (2012) J Immunol , vol.189 , pp. 1360-1371
    • Hilpert, J.1    Grosse-Hovest, L.2    Grünebach, F.3    Buechele, C.4    Nuebling, T.5    Raum, T.6
  • 18
    • 0020428728 scopus 로고
    • Low natural killer cell activity in patients with malignant lymphoma
    • Tursz, T, Dokhelar, MC, Lipinski, M and Amiel, JL (1982). Low natural killer cell activity in patients with malignant lymphoma. Cancer 50: 2333-2335.
    • (1982) Cancer , vol.50 , pp. 2333-2335
    • Tursz, T.1    Dokhelar, M.C.2    Lipinski, M.3    Amiel, J.L.4
  • 19
    • 0032924630 scopus 로고    scopus 로고
    • The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease
    • Konjevic, G, Jurisic, V, Banicevic, B and Spuzic, I (1999). The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol 104: 144-151.
    • (1999) Br J Haematol , vol.104 , pp. 144-151
    • Konjevic, G.1    Jurisic, V.2    Banicevic, B.3    Spuzic, I.4
  • 20
    • 42449102990 scopus 로고    scopus 로고
    • Up on the tightrope: Natural killer cell activation and inhibition
    • Lanier, LL (2008). Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495-502.
    • (2008) Nat Immunol , vol.9 , pp. 495-502
    • Lanier, L.L.1
  • 21
    • 77955983259 scopus 로고    scopus 로고
    • Anti-CD30 Antibodies for Hodgkin lymphoma
    • Foyil, KV and Bartlett, NL (2010). Anti-CD30 Antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 5: 140-147.
    • (2010) Curr Hematol Malig Rep , vol.5 , pp. 140-147
    • Foyil, K.V.1    Bartlett, N.L.2
  • 22
    • 79954438055 scopus 로고    scopus 로고
    • Hodgkin's lymphoma: Current treatment strategies and novel approaches
    • Eichenauer, DA, Fuchs, M, Borchmann, P and Engert, A; German Hodgkin Study Group (2008). Hodgkin's lymphoma: current treatment strategies and novel approaches. Expert Rev Hematol 1: 63-73.
    • (2008) Expert Rev Hematol , vol.1 , pp. 63-73
    • Eichenauer, D.A.1    Fuchs, M.2    Borchmann, P.3    Engert, A.4
  • 23
    • 79955877897 scopus 로고    scopus 로고
    • Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment
    • Steidl, C, Connors, JM and Gascoyne, RD (2011). Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 29: 1812-1826.
    • (2011) J Clin Oncol , vol.29 , pp. 1812-1826
    • Steidl, C.1    Connors, J.M.2    Gascoyne, R.D.3
  • 24
    • 0034060217 scopus 로고    scopus 로고
    • Frequent lack of translation of antigen presentation-associated molecules MHC class I, CD1a and Beta(2)-microglobulin in Reed-Stern berg cells
    • Van den Berg, A, Visser, L, Eberwine, J, Dadvand, L and Poppema, S (2000). Frequent lack of translation of antigen presentation-associated molecules MHC class I, CD1a and Beta(2)-microglobulin in Reed-Sternberg cells. Int J Cancer 86: 548-552.
    • (2000) Int J Cancer , vol.86 , pp. 548-552
    • Van Den Berg, A.1    Visser, L.2    Eberwine, J.3    Dadvand, L.4    Poppema, S.5
  • 25
    • 47249093196 scopus 로고    scopus 로고
    • Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D
    • Krockenberger, M, Dombrowski, Y, Weidler, C, Ossadnik, M, Hönig, A, Häusler, S et al. (2008). Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180: 7338-7348.
    • (2008) J Immunol , vol.180 , pp. 7338-7348
    • Krockenberger, M.1    Dombrowski, Y.2    Weidler, C.3    Ossadnik, M.4    Hönig, A.5    Häusler, S.6
  • 26
    • 80054703162 scopus 로고    scopus 로고
    • Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression
    • Mittelbronn, M, Platten, M, Zeiner, P, Dombrowski, Y, Frank, B, Zachskorn, C et al. (2011). Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 122: 353-365.
    • (2011) Acta Neuropathol , vol.122 , pp. 353-365
    • Mittelbronn, M.1    Platten, M.2    Zeiner, P.3    Dombrowski, Y.4    Frank, B.5    Zachskorn, C.6
  • 27
    • 79960637590 scopus 로고    scopus 로고
    • Protein targeting and degradation are coupled for elimination of mislocalized proteins
    • Hessa, T, Sharma, A, Mariappan, M, Eshleman, HD, Gutierrez, E and Hegde, RS (2011). Protein targeting and degradation are coupled for elimination of mislocalized proteins. Nature 475: 394-397.
    • (2011) Nature , vol.475 , pp. 394-397
    • Hessa, T.1    Sharma, A.2    Mariappan, M.3    Eshleman, H.D.4    Gutierrez, E.5    Hegde, R.S.6
  • 28
    • 79959906869 scopus 로고    scopus 로고
    • Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase
    • Jiang, W, Wang, S, Xiao, M, Lin, Y, Zhou, L, Lei, Q et al. (2011). Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell 43: 33-44.
    • (2011) Mol Cell , vol.43 , pp. 33-44
    • Jiang, W.1    Wang, S.2    Xiao, M.3    Lin, Y.4    Zhou, L.5    Lei, Q.6
  • 29
    • 34147156192 scopus 로고    scopus 로고
    • HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53
    • Sasaki, T, Gan, EC, Wakeham, A, Kornbluth, S, Mak, TW and Okada, H (2007). HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev 21: 848-861.
    • (2007) Genes Dev , vol.21 , pp. 848-861
    • Sasaki, T.1    Gan, E.C.2    Wakeham, A.3    Kornbluth, S.4    Mak, T.W.5    Okada, H.6
  • 30
    • 78650689674 scopus 로고    scopus 로고
    • Hodgkin's lymphoma: The role of cell surface receptors in regulation of tumor cell fate
    • Yurchenko, M and Sidorenko, SP (2010). Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate. Exp Oncol 32: 214-223.
    • (2010) Exp Oncol , vol.32 , pp. 214-223
    • Yurchenko, M.1    Sidorenko, S.P.2
  • 31
    • 0032855541 scopus 로고    scopus 로고
    • A bispecifc diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors
    • Arndt, MA, Krauss, J, Kipriyanov, SM, Pfreundschuh, M and Little, M (1999). A bispecifc diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 94: 2562-2568.
    • (1999) Blood , vol.94 , pp. 2562-2568
    • Arndt, M.A.1    Krauss, J.2    Kipriyanov, S.M.3    Pfreundschuh, M.4    Little, M.5
  • 32
    • 0036644046 scopus 로고    scopus 로고
    • Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells
    • Pisegna, S, Zingoni, A, Pirozzi, G, Cinque, B, Cifone, MG, Morrone, S et al. (2002). Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells. J Immunol 169: 68-74.
    • (2002) J Immunol , vol.169 , pp. 68-74
    • Pisegna, S.1    Zingoni, A.2    Pirozzi, G.3    Cinque, B.4    Cifone, M.G.5    Morrone, S.6
  • 33
    • 84856836302 scopus 로고    scopus 로고
    • High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas
    • Zocchi, MR, Catellani, S, Canevali, P, Tavella, S, Garuti, A, Villaggio, B et al. (2012). High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood 119: 1479-1489.
    • (2012) Blood , vol.119 , pp. 1479-1489
    • Zocchi, M.R.1    Catellani, S.2    Canevali, P.3    Tavella, S.4    Garuti, A.5    Villaggio, B.6
  • 34
    • 41549163195 scopus 로고    scopus 로고
    • NKG2D-defcient mice are defective in tumor surveillance in models of spontaneous malignancy
    • Guerra, N, Tan, YX, Joncker, NT, Choy, A, Gallardo, F, Xiong, N et al. (2008). NKG2D-defcient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
    • (2008) Immunity , vol.28 , pp. 571-580
    • Guerra, N.1    Tan, Y.X.2    Joncker, N.T.3    Choy, A.4    Gallardo, F.5    Xiong, N.6
  • 35
    • 77954613267 scopus 로고    scopus 로고
    • The prognostic signifcance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia
    • Nückel, H, Switala, M, Sellmann, L, Horn, PA, Dürig, J, Dührsen, U et al. (2010). The prognostic signifcance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24: 1152-1159.
    • (2010) Leukemia , vol.24 , pp. 1152-1159
    • Nückel, H.1    Switala, M.2    Sellmann, L.3    Horn, P.A.4    Dürig, J.5    Dührsen, U.6
  • 36
    • 33845987986 scopus 로고    scopus 로고
    • Defcient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
    • Fauriat, C, Just-Landi, S, Mallet, F, Arnoulet, C, Sainty, D, Olive, D et al. (2007). Defcient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109: 323-330.
    • (2007) Blood , vol.109 , pp. 323-330
    • Fauriat, C.1    Just-Landi, S.2    Mallet, F.3    Arnoulet, C.4    Sainty, D.5    Olive, D.6
  • 37
    • 80155132470 scopus 로고    scopus 로고
    • Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition
    • Mamessier, E, Sylvain, A, Bertucci, F, Castellano, R, Finetti, P, Houvenaeghel, G et al. (2011). Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71: 6621-6632.
    • (2011) Cancer Res , vol.71 , pp. 6621-6632
    • Mamessier, E.1    Sylvain, A.2    Bertucci, F.3    Castellano, R.4    Finetti, P.5    Houvenaeghel, G.6
  • 38
    • 79958118266 scopus 로고    scopus 로고
    • Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
    • Delahaye, NF, Rusakiewicz, S, Martins, I, Ménard, C, Roux, S, Lyonnet, L et al. (2011). Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 17: 700-707.
    • (2011) Nat Med , vol.17 , pp. 700-707
    • Delahaye, N.F.1    Rusakiewicz, S.2    Martins, I.3    Ménard, C.4    Roux, S.5    Lyonnet, L.6
  • 39
    • 80052346280 scopus 로고    scopus 로고
    • Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
    • Mamessier, E, Sylvain, A, Thibult, ML, Houvenaeghel, G, Jacquemier, J, Castellano, R et al. (2011). Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121: 3609-3622.
    • (2011) J Clin Invest , vol.121 , pp. 3609-3622
    • Mamessier, E.1    Sylvain, A.2    Thibult, M.L.3    Houvenaeghel, G.4    Jacquemier, J.5    Castellano, R.6
  • 40
    • 0030974954 scopus 로고    scopus 로고
    • Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecifc antibody
    • Hartmann, F, Renner, C, Jung, W, Deisting, C, Juwana, M, Eichentopf, B et al. (1997). Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecifc antibody. Blood 89: 2042-2047.
    • (1997) Blood , vol.89 , pp. 2042-2047
    • Hartmann, F.1    Renner, C.2    Jung, W.3    Deisting, C.4    Juwana, M.5    Eichentopf, B.6
  • 41
    • 33646559241 scopus 로고    scopus 로고
    • Deciphering CD30 ligand biology and its role in humoral immunity
    • Kennedy, MK, Willis, CR and Armitage, RJ (2006). Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118: 143-152.
    • (2006) Immunology , vol.118 , pp. 143-152
    • Kennedy, M.K.1    Willis, C.R.2    Armitage, R.J.3
  • 42
    • 0037716818 scopus 로고    scopus 로고
    • Natural killer cell receptor signaling
    • Lanier, LL (2003). Natural killer cell receptor signaling. Curr Opin Immunol 15: 308-314.
    • (2003) Curr Opin Immunol , vol.15 , pp. 308-314
    • Lanier, L.L.1
  • 43
    • 0034076307 scopus 로고    scopus 로고
    • Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
    • Clynes, RA, Towers, TL, Presta, LG and Ravetch, JV (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446.
    • (2000) Nat Med , vol.6 , pp. 443-446
    • Clynes, R.A.1    Towers, T.L.2    Presta, L.G.3    Ravetch, J.V.4
  • 45
    • 33845944538 scopus 로고    scopus 로고
    • Tumor-primed human natural killer cells lyse NK-resistant tumor targets: Evidence of a two-stage process in resting NK cell activation
    • North, J, Bakhsh, I, Marden, C, Pittman, H, Addison, E, Navarrete, C et al. (2007). Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol 178: 85-94.
    • (2007) J Immunol , vol.178 , pp. 85-94
    • North, J.1    Bakhsh, I.2    Marden, C.3    Pittman, H.4    Addison, E.5    Navarrete, C.6
  • 47
    • 84863676500 scopus 로고    scopus 로고
    • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
    • Younes, A, Gopal, AK, Smith, SE, Ansell, SM, Rosenblatt, JD, Savage, KJ et al. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30: 2183-2189.
    • (2012) J Clin Oncol , vol.30 , pp. 2183-2189
    • Younes, A.1    Gopal, A.K.2    Smith, S.E.3    Ansell, S.M.4    Rosenblatt, J.D.5    Savage, K.J.6
  • 48
    • 84867580896 scopus 로고    scopus 로고
    • T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecifc tetravalent antibody CD19 × CD3 or CD19 × CD16
    • Pörtner, LM, Schönberg, K, Hejazi, M, Brünnert, D, Neumann, F, Galonska, L et al. (2012). T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecifc tetravalent antibody CD19 × CD3 or CD19 × CD16. Cancer Immunol Immunother 61: 1869-1875.
    • (2012) Cancer Immunol Immunother , vol.61 , pp. 1869-1875
    • Pörtner, L.M.1    Schönberg, K.2    Hejazi, M.3    Brünnert, D.4    Neumann, F.5    Galonska, L.6
  • 49
    • 42449123606 scopus 로고    scopus 로고
    • Natural killer cell-directed therapies: Moving from unexpected results to successful strategies
    • Terme, M, Ullrich, E, Delahaye, NF, Chaput, N and Zitvogel, L (2008). Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9: 486-494.
    • (2008) Nat Immunol , vol.9 , pp. 486-494
    • Terme, M.1    Ullrich, E.2    Delahaye, N.F.3    Chaput, N.4    Zitvogel, L.5
  • 50
    • 33344477900 scopus 로고    scopus 로고
    • A novel bispecifc protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
    • von Strandmann, EP, Hansen, HP, Reiners, KS, Schnell, R, Borchmann, P, Merkert, S et al. (2006). A novel bispecifc protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107: 1955-1962.
    • (2006) Blood , vol.107 , pp. 1955-1962
    • Von Strandmann, E.P.1    Hansen, H.P.2    Reiners, K.S.3    Schnell, R.4    Borchmann, P.5    Merkert, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.